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Trials, Tribulations, and Trends in Tumor Modeling in Mice
JOANN C. L. SCHUH
Applied Veterinary Pathobiology, Bainbridge Island, Washington 98110-3663, USA
ABSTRACT
Selection of mouse models of cancer is often based simply on availability of a mouse strain and a known compatible tumor. Frequently this results
in use of tumor models long on history but short on homology and quality control. Other factors including genetics, sex, immunological status, method
and site of tumor implantation, technical competence, biological activity of the tumor, protocol sequence and timing, and selection of endpoints interact
to produce outcomes in tumor models. Common reliance on survival and tumor burden data in a single mouse model often skews expectations towards
high remission and cure rates; a finding seldom duplicated in clinical trials. Inherent limitations of tumor models coupled with the advent of new
therapeutic targets reinforce need for careful attention to design, conduct, and stringent selection of in vivo and ex vivo endpoints. Preclinical efficacy
testing for anti-tumor therapies should progress through a series of models of increasing sophistication that includes incorporation of genetically
engineered animals, and orthotopic and combination therapy models. Pharmacology and safety testing in tumor-bearing animals may also help to
improve predictive value of these models for clinical efficacy. Trends in bioinformatics, genetic refinements, and specialized imaging techniques are
helping to maintain mice as the most scientifically and economically powerful model of malignant neoplasms.
Keywords. Preclinical efficacy testing; tumor models; study design; xenograft; orthotopic tumors; genetically engineered mice; bioinformatics;
bioimaging.

INTRODUCTION
Malignant neoplasms rank second as the leading cause
of death in the United States and ranked first in those aged
45–74 (Anderson, 2002). As a result, anti-cancer therapies
are a frequent focus for startup companies and represent major therapeutic classes for pharmaceutical, biopharmaceutical, medical device and drug delivery manufacturers. Despite
the effort applied to cancer targets, the number of successful
new therapies for treating human malignancies is discouragingly low. This is surprising in that many trials are now
conducted using novel agents with specificity for molecular pathways and cellular components rather than broad targeting of chemotherapy and radiation to normal and neoplastic cells. Failures in clinical trials are multifactorial with
lack of efficacy an important cause. Conversely, modulating
and curing experimental cancer in mice is a relatively easy
process. Many commonly used mouse models of neoplasia
have proven to be biased towards false positive results and
preclinical studies have not accurately predicted clinical responses. Therefore, unconditional acceptance of limited data
from mouse models has to be avoided to prevent premature
movement of development programs into clinical testing. Increasingly, the plethora of novel strategies undergoing testing requires greater attention to proper design and conduct
of preclinical efficacy studies. Rationale design of preclinical
efficacy studies requires understanding the biology of tumors
and implantation techniques, selection of in vivo and ex vivo
endpoints, and a willingness to integrate new and often costly
testing strategies that more appropriately mimic the biology
of human neoplasms.

BIOMEDICAL MODELS OF NEOPLASIA
FOR PRECLINICAL TESTING
Spontaneous and Environmental Carcinogenesis Models
Historically, spontaneous, chemical, ultraviolet (UV),
oncogene, and viral infection models helped to define many
aspects of carcinogenesis (Harrison, 2002) and therapeutic
intervention (Boone et al., 1992) and helped to promote development of inbred strains of mice (Corbett et al., 2002).
Despite the significance of spontaneous and environmental
models to biomedical research, the long latency of most of
these models makes them impractical for most preclinical
studies of tumor modulation. Spontaneous, chemical and UV
and viral infected or transformed tumors are of greatest importance as the source of many cells lines used for in vitro
studies and in vivo transplantation models.
Transplantation Models
There are many immortalized cell lines of human and
murine origin available from commercial sources and privately held by research organizations that have been tested
for tumorigenicity in mice (Giard et al., 1973; Gershwin et al.,
1977; Fogh et al., 1977; Trainer et al., 1988). In addition to
availability, these tumorigenic cell lines are generally easy to
maintain, selectable for unique mutations in vitro and backed
by numerous publications on in vivo behavior in immunodeficient (nude, beige, nude/beige, C.B -17 severe combined immunodeficient [SCID], nonobese diabetic [NOD]/SCID), immunosuppressed (thymectomized or corticosteroid treated),
humanized (hu)-SCID or hu-NOD/SCID and immunocompetent strains of mice. However, quality control is an issue. Many cell lines have undocumented source and passage histories, poorly characterized receptor and oncogene
expression and cellular secretions, and inconsistent designations in publications. Features that make these tumor lines
suitable for transplantation may affect experimental design
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because of the need for specific mouse strains, sex specificity, and altered host immunity. Furthermore, spontaneous
mutations in vitro that allow selection of tumor cell line
subclones with unique behaviors can also result in point
mutations that lead to changes in histomorphology, sensitivity, and behavior of these tumors in vivo. Dissociated
solid tumors and fragments of tumors (explants) that retain
histomorphology relationships of the tumor and associated
stroma are also suitable for implantation (Gershwin et al.,
1977). Tumor cells from cell lines and solid masses of both
human and mouse origin may require handling as biohazardous material due to their histogenesis by viral transformation or inadvertent contamination (Hay, 1991; Nicklas
et al., 1993). The literature on tumors that have been used
in mice to model important therapeutic targets in humans is
vast. Due to the rapidly changing nature of biomedical research, a thorough and current literature search is warranted
prior to selecting the most appropriate models for any therapeutic development program. A selection of representative
mouse models (transplantation and genomic-based) for malignant neoplasms causing death in humans is provided in
Table 1.
Criteria other than historical usage, and availability of the
tumor line and a suitable mouse host need to be considered
when testing efficacy of tumor modulation with therapeutics (Skipper, 1968; Huseby, 1969; Klausner, 1999). Even
with genetically engineered models, multistep progression
and clonal derivation of tumors in humans are difficult to
model in mice. Therefore, foibles of these models need to be
understood to prevent overinterpretation of positive or negative results.
CONSIDERATIONS IN SELECTING TUMOR MODELS IN MICE
It is well recognized that our understanding of modeling
of tumor biology and therapeutic intervention is constrained
by many factors (Siemann, 1987; Rew, 2000a; Rew, 2000b).
However, validation studies of these model systems for their
ability to adequately predict therapeutic responses in patients
have been rare (Hann and Balmain, 2001). Consequently, design and interpretation of preclinical studies for tumor modeling must be undertaken carefully.
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Study Design
Candidate anti-tumor agents can be identified and selected
using a broad panel of in vivo tumors (Atassi et al., 1988)
but false positive and negative results may occur due to incompatible host-tumor-therapeutic interactions or technical
incompetence. In efficacy studies, greater depth needs to be
achieved through evaluation of at least several subtypes of
the tumor representative of the clinical target, and through
use of different models systems in mice (transplantation, genetically engineered, and orthotopic models) as well as use
of models in other appropriate species. Conduct of animal
studies that mimic expected exposure, scheduling, and duration of therapeutic and posttreatment periods of clinical
studies are valuable designs prior to initiating clinical trials.
Optimization of therapeutic dose and schedule through pharmacokinetic studies are also important early procedures that
should be evaluated in one or more model systems. Efficacy
studies should also incorporate histopathology endpoints to
confirm expected therapeutic target and to help refine dose
scheduling relative to growth and cell loss fractions.
Investigators need to be aware that many historical and
commonly used model systems in mice were originally established and optimized for use in mechanistic studies (Burger,
2000). Conduct of efficacy testing in such systems has not
been optimized and inadvertent selection of systems with
excess curability, spontaneous regressions or failure to establish adequate tumor burden (Corbett et al., 2002) can lead
to overly optimistic projections of clinical success. Bias in
the selection of the model(s) may also arise from experience,
knowledge base and objectives of the investigator. Whereas
pharmacologists, immunobiologists or cell biologists may
consider direct intratumoral injection of therapeutics acceptable, needle tracks and pressure-induced necrosis (compartment syndrome) may interfere with adequate evaluation of
such models by a histopathologist. Conversely, intratumoral
administration of light activated substances is a common
and appropriate route for photodynamic therapy of tumors
(Casas et al., 1999). Design of efficacy studies for combination protocols is often difficult. However, such studies can
provide important efficacy data for the transition between
novel therapies and standard treatment practices that may

TABLE 1.—Rank order of deaths due to malignant neoplasms in the United States in 2001 (Arias and Smith, 2003) and selected published reviews on applicable
mouse models of these neoplasms.
Rank

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Malignant Neoplasms

Cases

Selected Mouse Models

Lung—trachea
Colon—rectum
Lymphoid—hematopoietic
Breast
Prostate
Pancreas
Ovary
Liver
Brain—meninges
Esophagus
Stomach
Bladder
Kidney
Oral
Skin
Uterus
Cervix
Larynx

156,005
56,799
56,350
41,844
30,714
29,723
14,361
13,263
12,567
12,509
12,340
12,115
12,084
7,638
7,543
6,835
4,064
3,826

Tuveson and Jacks, 1999; Malkinson, 2001; Liu and Johnston, 2002
Heyer et al., 1999; Kobaek-Larsen et al., 2000; Horig et al., 2001; Boivin et al., 2003
Dykes and Waud, 2002; Uckun and Sensel, 2002; Vanderkerken et al., 2003
Hutchinson and Muller, 2000; Cardiff, 2001; Rosner et al., 2002; Clarke, 2002
Royal et al., 1996; Navone et al., 1999; Abate-Shen and Shen, 2002; Nyska et al., 2002
Fu et al., 1992; Hotz et al., 2000; Standop et al., 2001; Bardeesy et al., 2001
Rahman et al., 1998; Rahman and Huhtaniemi, 2001; Orsulic et al., 2002
Fausto, 1999; Feitelson and Larkin, 2001
Holland, 2001; Reilly and Jacks, 2001; Begemann et al., 2002; Gutmann et al., 2003
Opitz et al., 2002
Furukawa et al., 1993b
Eto et al., 2000; Bonfil et al., 2002
Naito et al., 1987b; An et al., 1999; Hillman, 2002
Waters et al., 1998; Myers et al., 2002
Alvarez, 2002; Eccles, 2002; Carson III and Walker, 2002
Couse et al., 1997; Keshavarzi et al., 2002
Herber et al., 1996
Chen et al., 2001; Kennel et al., 2002
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include a combination of surgery, chemotherapy or radiation,
and other supportive therapies (Bogden et al., 1974; Corbett
et al., 1979). In designing tumor model systems, investigators
must guard against template designs that ignore inherent differences in model systems, and in using insufficient animals
per group. This is particularly important in investigational
new drug (IND) enabling studies where more animals per
group and few groups may be required to adequately control for variation in tumor burden and therapeutic responses.
Consultation with a biostatistician to assist in determination
of sample size appropriate to each model system is highly
recommended.
Context of the Study and Available Resources
Therapeutic intervention conducted in tumor-bearing animals may occur as proof of principal studies for discovery,
target validation, and in vivo pharmacology, or as investigations for therapeutic efficacy, safety, and interactions. These
types of studies often need to be designed and conducted
differently than studies focusing on mechanistic studies. Additionally, an available supply of suitable strains of mice and
investigators capable of providing necessary manipulations
(injections, surgery, polytherapy, evaluations, and pathology
services) may materially affect both quantity and quality of
data that can be generated from selected models.
Lack of Quality Control
Investigators using cell lines should develop and maintain
in-house databases that allow ready access to known features
for tumor cell lines in their collections. A minimum list might
include all applicable information that defines origin (human
or animal), sex and strain of original host, treatment history
(particularly human lines), name and subclone of the tumor
line, source (commercial or private), passage history of all
aliquots, species, strain and sex and routes susceptible to implanted tumors, in vitro and in vivo growth characteristics,
growth rate to maximum humanely accepted and lethal sizes,
histomorphological characteristics, metastatic potential and
method, immunogenicity, receptor and oncogene expression,
cellular products, microbiological screening history, biohazard potential (generally viral) and unique characteristics. This
information is invaluable for preventing and investigating
problems such as implantation failures, excess curability,
microbial contamination, mislabeled or cross-contaminated
stocks, and alterations in histomorphology and behavior that
may arise from haphazard use of cell lines (Corbett et al.,
2002). With rare exception (Rosner et al., 2002), thorough
characterization of comparative histology of tumor models
using authenticated stocks has not been adequate. Additionally, microbial and cross-species contamination of cell lines
has lead to erroneous conclusions in tumor biology (Moseley
et al., 2003; Drexler et al., 2003). These problems are compounded by lack of source and passage history information
reported by most laboratories conducting either mechanistic
or efficacy studies. This is not a trivial problem, as the histomorphology and behavior of tumors grown from stocks in
different laboratories may eventually differ from historical
photomicrographs and behavior descriptions of the original
tumor and its cell line (Schuh, unpublished data). Although
the original passage history may not be known, investigators
should strive to use contaminant free tumor lines of a con-
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sistent number of passages from an authenticated stock for
preclinical testing. In addition to providing a known in-house
passage history, testing from a stock provides a baseline and
helps to reduce the potential for point mutations that may
cause inter-study variation or erroneous test results.
Paraneoplastic Syndromes
Paraneoplastic syndromes typically result in clinical
manifestations of altered physiological responses to autochthonous (spontaneous) neoplasms. These syndromes in
mouse models of neoplasia have been seldom described
(Liebelt et al., 1974) even though they exist. This oversight
is brought on by the focused and short-term nature of most
studies. Unlike safety studies where a complete set of tissues are collected and a clinical pathology examination conducted, efficacy studies are often completed without benefit of histopathology and clinical pathology examinations.
This type of study design neglects important interactions
of the host with tumor receptor expression and secretions
produced by tumor cells or by stimulation of host cells by
the tumor. Paraneoplastic syndromes include extramedullary
hematopoiesis, bone marrow hyperplasia, peripheral granulocytosis and leukocytosis (leukemoid reactions), thrombocytosis, anemia, altered lipid metabolism, hypercalcemia of
malignancy, hypoglycemia, cachexia and organomegaly in
nontumor-bearing tissues (Liebelt et al., 1974; Castillo et al.,
1982; Yoneda et al., 1991; Tanaka et al., 1996; Diament et al.,
1998, Schuh, unpublished data). Paraneoplastic syndromes
represent potential models for similar syndromes in humans
but causation are poorly characterized and effects of these
syndromes on pharmacology, safety, and efficacy studies using experimental tumors are unknown.
Transplantation Protocols: Sites of Implantation Can Affect
Study Outcome
Autogeneic or autochthonous tumors are seldom practical
for tumor modeling for therapeutic intervention. Most transplantable tumors are placed heterotopically (ectopically) in
syngeneic (same species, genetically identical), allogeneic
(same species, genetically different) or xenogeneic (different species and genetics) host systems. Tumor lines in use
have been specifically selected for mutations that allow heterotopic growth in mice. Although these tumors will grow
and respond to therapeutics, heterotopic sites are not ideal
and selection of the transplantation site may modulate tumor
growth (Naito et al., 1987a; Corbett et al., 2002) and success
of therapeutic intervention (Averbook et al., 2002).
Subcutaneous (SQ) and less frequently intradermal areas are used for primary tumors for reasons of accessibility, lack of distress and interference with mobility in mice,
and visibility for monitoring. Generally, SQ refers to placement by injection or surgical implantation in the flank, a region referring to the posterior lateral abdominal quadrant.
Some investigators erroneously include the hindlimb, back
and axillary region in their description of the flank. Placement is generally done in fat and mammary gland tissues
near popliteal, inguinal or accessory axillary lymph nodes.
Despite the common use of SQ sites, it is important to note
that even large tumors rarely, if ever, metastasize after implantation in this site (Gershwin et al., 1977; Eccles, 2002).
Implantation in the hindlimb (including popliteal lymph node
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fat) is sometimes considered superior to placement near body
cavities for improved visualization and avoidance of accidental intra-peritoneal or -thoracic implantation. Rarely, tumors
may not be viable after SQ implantation and other sites may
be required. Implantation of tumors into footpads is generally
not acceptable for humane considerations (UKCCCR, 1998;
Wallace, 2000). Intramuscular implantation is not common
as cell lines and tumor explants may not grow well in muscle
compared to SQ, leg mobility is restricted by large masses,
expansion space is limited, measurements with calipers are
more difficult and this site appears to be more prone to selfmutilation and a target for cage mate aggression. Fat pads
other than classic SQ sites, including retroperitoneal, epididymal, intrascapular and mediastinal/thymic sites are also
valuable locations for injection and surgical implantation to
provide a highly vascular milieu that appears to assist in establishment of xenogeneic tumors. A comparison of tumor
viability in brown fat in interscapular areas, compared to the
predominate white fat in other fat pads does not appear to
have been made.
Primary and sometimes metastatic models are also established by direct surgical or percutaneous intra-organ injections into spleen, liver, lymph nodes, mammary gland,
prostate, base of the tongue (head and neck carcinoma), intraluminal (bronchial, urinary bladder, thorax), cecal wall implantation (colorectal metastases), and kidney capsule. Injection into brain and eye are often not considered acceptable
by institutional animal care and use committees (IACUC)
(UKCCCR, 1998; Wallace, 2000).
Metastatic and sometimes primary tumor models are created by intravenous, intracardiac (ventricle), intraosseous injections or intravascular injections proximal to organs (e.g.,
portal vein for liver neoplasms). Despite careful preparation
to reduce cell clumps and to inject slowly, such tumors are
embolic and may grow in unintended sites. Most tumors show
selective tissue tropisms, but tumors with broad tropism (e.g.,
lymphoma/leukemia) may grow within all tissues and result
in large unmonitorable tumor burdens (Schuh, unpublished
data). Investigators rarely evaluate tissues for metastases outside of their specific area of interest (most often lung and
bone) so that characterization of additional tumor burdens
and thromboembolism of tumor cells on validity of these tumor models is lacking. Intraperitoneal injections of tumors,
once a common route for leukemias and metastatic models, have humane considerations that need to be considered
(UKCCCR, 1998; Wallace, 2000).
Implantation techniques must be practiced, as accidental
injection into muscle masses or visceral cavities, and postsurgical inflammation can cause intra-study variability and
lack of interstudy reproducibility. Migration through SQ tissues or leakage of cell suspensions is generally not an issue
with proper technique and minimal volumes injected with a
small gauge needle. Interstudy reproducibility of implanted
tumor burdens may be affected by extent of cell separation,
particularly for disruption of in vitro cultures or solid tumors (An et al., 1999). In some efficacy studies, surgical
implantation of hollow fibers (Sadar et al., 2002), matrigel
and discs (Eccles, 2002), polymers (Righi et al., 2003), liposomes (Kunstfeld et al., 2003), and transparent windows
(Dellian et al., 1996; Li et al., 2000; Jain et al., 2002) can
provide a tightly contained tumor environment to optimize
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reproducibility for certain endpoints such as angiogenesis.
Inflammation and interference with tumor biology must be
considered when utilizing surgically implanted devices for
containment of tumor masses.
Other Host-Tumor-Therapeutic Interactions
Differences in tumor burden potential, angiogenic and therapeutic response have been shown to be due to differences in
strains of mice tested (Naito et al., 1987b), primary implantation site and interval between tumor implantation and therapeutic manipulations (Wilmanns et al., 1992; Chakrabarty
et al., 1994; Averbook et al., 2002; Monsky et al., 2002), and
metastatic microenvironments (Averbook et al., 2002; Seki
et al., 2003). For xenogeneic and syngeneic tumors that require immunodeficient mice, differences in immunological
defects between these strains should be understood. Similarly, immunogenicity of tumors in immunocompetent hosts
may be an important modifying factor. Other factors that
can affect tumor growth in vivo include concurrent manipulations such as surgery, radiation or concurrent treatments
that produce inflammation and inhibit establishment of tumor
cells. Conversely, stress and seasonal effects may increase
tumor burden and distribution (Giraldi et al., 2000). Finally,
for long standing tumors, tumor-induced cachexia may suppress tumor growth and enhance efficacy (Laster et al., 1961;
Chakrabarty et al., 1994; Mukherjee et al., 2002), similar to
delays in tumor development found with intentional caloric
restriction in rodents (Suttie et al., 2003). Therapeutic efficacy
is also modulated through tissue specific and immunologic
modifiers, and differences in drug metabolism and disposition (Gershwin et al., 1977; Naito et al., 1987a; Wilmanns
et al., 1992; Averbook et al., 2002; Seki et al., 2003).
Specific strains of mice used for tumor models are usually
matched to origin of the transplanted tumor. Where multiple tumor cell lines are available to model certain tumors,
unique characteristics of these tumors such as host origin,
oncogenes, receptors and secretions, and tumor stage may
be an important consideration. However, these parameters
are often difficult to match to comparable stages in humans
(Harrison, 2002). With these limitations in available models,
selection of or reporting only on tumors that are dramatically
and positively affected by test therapeutics should be avoided.
Testing therapeutic interventions on similar tumor types derived from multiple cell lines provides a test situation that
partially addresses heterogeneity of tumors in humans. That
some of these tumors may not be modulated by the test therapeutic should be expected, and these nonresponders should
not be treated as preclinical failures or dismissed. Rather,
both negative and positive tumor responses can provide investigators with a more realistic expectation of therapeutic
potential in humans, and the totality of the response across
several models provides superior insight into activity of
therapeutics.
ENDPOINTS AND EVALUATION CRITERIA FOR TUMOR
MODELS IN VIVO
Critical host-tumor-therapeutic interactions, doseresponse, treatment protocol design, and selection of
endpoints interact to produce outcomes in tumor modeling
(Skipper, 1990; Kerbel, 1999). The goal in clinical oncology
is regulation to improve survival and quality of life, and
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to prevent recurrent disease rather than to cure/kill cancer
(Schipper et al., 1995). More stringent criteria than curability
of experimental tumors in mice need to be assessed to determine therapeutic efficacy. Counts of tumor bearing animals
and measurement of tumor burden are the easiest and most
frequently used outcomes of efficacy in preclinical studies.
In reality, endpoints need to be matched to type of tumor
(solid, leukemia or metastatic), context of the study, accessibility of the implantation site, type of implantation, and
therapeutic class. Simplistic criteria used in mouse models
do not match criteria of partial and complete responses used
in clinical oncology, and they contribute to the conflicting
opinions about the relevance and predictability of mouse
models. Therefore, use of other metrics, and evaluations
of angiogenesis, immunomodulation, metastases, and
detailed histopathology need to be incorporated into most
study designs for preclinical testing. Despite the technical
difficulty, labor-intensive nature, and expense commonly
cited as limitations for detailed examinations, the utility
of mouse models is improved by multiple and appropriate
endpoints (Table 2).
In Vivo Endpoints
Tumor growth inhibition studies where treatment is prophylactically administered before or on the day of tumor induction are not realistic for preclinical evaluation of clinical responses. Typically, preclinical efficacy studies utilize
tumor growth delay in which tumors are induced by injection or surgical implantation and allowed to establish for
a number of days prior to initiation of treatment. Solid tu-
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mors in accessible sites are amenable to a variety of metrics that are not applicable to primary and metastatic tumors
of internal organs and hematologic neoplasms. A count of
tumor-bearing animals assumes that nontumor-bearing animals represent tumor regression or cures. Spontaneous regressions, failure of tumors to become established or displaced tumor mass into adjacent body cavities may account
for a small percentage of false cures. For this reason, tumor
onset and progression should be monitored daily to ensure
adequate and similar tumor masses prior to treatment and
monitor onset of regression in each group. In models with
log-phase tumor growth, animals can be randomized into
treatment groups after a predictable period of development,
usually 3–14 days. Conversely, less well-developed tumor
models may require enrollment of individual animals into
the study when the tumor burden reaches a minimum size.
Such enrollment studies are difficult to evaluate. Allowing
extra days for tumor growth may be as misleading as starting
treatment on small tumor masses that have not established
and show enhanced regression after onset of treatment. In
vivo progression of tumor burden should be evaluated on
a daily basis, excluding tumor free animals as they appear.
Burden is commonly measured with calipers and volume estimated from measurement of two (length and width) dimensions (Corbett et al., 2002; Teicher, 2002). Estimates of tumor weight (length[width2 ]/2) using the typically inaccurate
measurements derived from tumors of varying shapes and
boundaries is not recommended. Tumor growth delay measures the difference in days for the mean or median tumors in
test and control animals to reach a specific volume, usually

TABLE 2.—Endpoints to evaluate preclinical efficacy of tumor models in mice.
Endpoint

Comment

Formulaa

In vivo

Tumor onset
Tumor progression
Number of tumor-bearing animals
Tumor burden—in vivo

Day of palpable tumor mass of preselected size
Daily plot of tumor burden
Tumor free assumes cure
Measured (mm2 )
Volume estimated (mm3 )—2-dimensional measurement

Tumor growth delay
Tumor cell kill

Delay to reach specific volume
1) Log10 total tumor cell kill
2) Net Log 10 tumor cell kill
Increase in mean or median lifespan or long-term survivors

Survival – life span or long-term

Length × width
Length × (width × 2)b
Length × (width2 ) × 0.5
T − C in days
1) (T − C in days)/3.32 × Td
2) (T − C) (duration of treatment in days)/3.32 × Td
T/C (%)

Ex Vivo

Survival—number alive
Tumor burden—gross pathology

Hematology
Histopathology

a

1) Treatment termination
2) Posttreatment
Length × width × depth
1) Volume estimated (mm3 )—2- or 3-dimensional measurements
2) Absolute weight (mass in mg as water displacement or wet weight)
3) Tumor weight relative to body weight
Tumor weight/body weight
4) Ulceration
5) Invasion or tissue distribution and gross lesions (e.g., infarction)
1) Complete blood count
2) Differential blood count
3) Bone marrow differential
1) Hematoxylin and eosin
a. Confirm histogenesis and differentiation
b. Identify invasion and metastases
c. Confirm expected therapeutic activity
d. Necrosis—characteristics and estimate percentage
e. Evaluate angiogenesis, hemorrhage, edema, and immune and
stromal responses
2) Morphometrics
3) Immunohistochemistry and in situ hybridization
4) Molecular pathology

T = test; C = control; Td = doubling time; 3.32 = doublings to increase 1 log10 unit.
Formulas used for volume estimates vary.

b
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0.5–1.0 cm3 . This value has been suggested to mimic clinical
endpoints and disease progression, but this measure is often
incorrectly applied. A 50% reduction in tumor mass as a measure of cytoreduction used to gauge clinical responsiveness is
not equivalent to 50% inhibition of tumor growth commonly
used as a measure of preclinical efficacy (Corbett et al., 2002;
Teicher, 2002). Tumor cell kill (net and total) for leukemic
or solid tumors requires tumor titration using 10-fold dilutions to determine doubling time, and comparison to tumor
growth delay and duration of treatment. Despite the value and
more exact nature of these determinations, extra time and additional test animals required generally result in infrequent
use of these endpoints (Corbett et al., 1999; Harrison, 2002;
Teicher, 2002). Survival data should not be mistaken for mortality, an unacceptable endpoint (UKCCCR, 1998; Wallace,
2000). An increase in percentage mean or median survival
may be measured for the lifespan or in long-term survivors.
Clinically, posttreatment survival is a valuable endpoint that
evaluates treatment efficacy during and after treatment. Survival at study termination is inadequate due to the short duration of most assays and lack of posttreatment data. For many
tumors, a log-linear growth cannot be assumed, and more
importantly, regrowth of tumors post-treatment may escalate due to increased doubling times (Gunduz et al., 1979;
Teicher, 2002). Retention of a subset of animals for several
weeks after treatment ends may demonstrate a rapid regrowth
of tumor at the efficacious dose that quickly parallels morbidity of controls and lower dose groups. In spite of a delay
in tumor growth over the treatment period, a rebound effect post-treatment would be an indication of lower overall
efficacy.
Ex Vivo Endpoints
At study termination, volume measurements similar to
those performed in vivo can be made at gross pathology,
but mass (water displacement) or absolute wet weight ex
vivo is more exacting. Volume measurements at termination
may show significant disparity from final in vivo measurements. Irregular shapes, small or multilobular masses and
necrosis, edema, and hemorrhage all contribute to variation
in estimates of tumor burden measurements. Relative tumor
to body weight ratios are often useful to gauge therapeutic efficacy in slow growing tumors and when cachexia is present.
The relative ratio can reduce or expand differences between
controls and treated animals and is a valuable and easily obtained supplement to absolute tumor weight. Visualization
and quantification of metastases is particularly difficult to
monitor as multifocal and occult tumor burdens are frequent.
Flooding of airways with India ink to highlight lung masses
for counting, “bread loafing” of the target organ for metastatic
counts and organ weight differences compared to controls are
inexact measurements prone to intra- and inter-study variability. Such models are better served by tagged tumors and
advanced imaging technologies. Gross pathology examination should evaluate presence or absence of ulceration, extent of intentional or inadvertent invasion, tissue distribution
beyond the primary implant site, and identify other gross lesions. Accidental implantation of tumors into body cavities
can skew results by partial growth of tumor at the intended
site that responds to treatment, along with a large internal
tumor burden that is unresponsive to treatment. Hematology
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(complete blood count and differential) and bone marrow differentials (smears or fluorescent activated cell sorting analysis) can provide data about paraneoplastic syndromes and
toxicity. However, hematology and histopathology endpoints
are often considered elective. Histologic screening of tumors
is valuable to confirm histogenesis and state of differentiation of tumors for quality control and to identify and separate
local invasion from metastasis. Characteristics of the tumor
such as necrosis, angiogenesis, hemorrhage and immune cell
and stromal responses should be monitored. More importantly, histology should confirm the expected activity and
target of the therapeutic class. Novel therapeutics currently
under development are driving the need for additional ex vivo
studies such as morphometry to evaluate angiogenesis and
apoptosis, immunohistochemistry, in situ hybridization and
molecular pathology to evaluate changes in macromolecules,
immunophenotypes and nucleic acids.
Pharmacology and Safety Endpoints
in Tumor-Bearing Animals
Toxicokinetic (TK), and absorption, distribution,
metabolism, and excretion (ADME) studies are generally
performed early in drug discovery (Lin et al., 2003) and are
often incorporated into anti-tumor protocols to determine
dose and scheduling. Conversely, safety testing is almost
exclusively performed in nontumor-bearing animals. Considering the altered homeostasis of most tumor-bearing
animals and humans, safety in a tumor-bearing host should
be considered to fully evaluate the therapeutic response and
potential. Adverse events can be monitored using a standard
safety protocol in tumor and a non-tumor-bearing mouse
model, but tolerability of treatment is more difficult to
monitor. Limited resources and economic restraints would
not support conduct of a full safety program in tumor-bearing
animals, but examination of a full panel of tissues from at
least one model may be useful to identify adverse effects,
modulation of paraneoplastic syndromes, and tolerability
issues. Although safety information is generally collected in
immunocompetent animals, use of immunodeficient strains
may be a better predictor of TK/ADME and safety as a
mimic of immune dysfunction after chemotherapy, radiation therapy, surgery (Wichmann et al., 2003), infections
and paraneoplastic syndromes (Tanaka et al., 1996). A
modified safety study can be incorporated into an efficacy
study by collecting a complete or selected list of tissues
from tumor-bearing animals and by including treated but
non-tumor-bearing animals as additional controls. Although
safety information in tumor-bearing animals may be incomplete, this data supplements efficacy, TK and ADME data
and can provide needed redirection in dosage and scheduling
for subsequent studies.
Humane Considerations
Therapeutic intervention trials may use both short-term
and long-term tumor growth models depending on growth
rate and aggressiveness of the tumor. Mortality should not be
used as an endpoint. Commonly used endpoints such as tumor
burden should be limited according to absolute values and
relative to body weight. Therefore, careful monitoring and
humane endpoints need to be developed in conjunction with
the IACUC. Ulceration, tissue and body cavity distension,
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inanition, cachexia, anemia, increased intracranial pressure,
self-mutilation, cannibalism, and metastases also contribute
to premature death of study animals and may require a limited
protocol or modified study design (UKCCCR, 1998; Wallace,
2000).
TRENDS IN TUMOR MODELING
Bioinformatics and Mouse Models of Cancer
The evolution of new mouse models of cancer is tightly
bound to knowledge gained from sequencing of human and
mouse genomes, and compilation and dissemination of this
knowledge on the World Wide Web. Important databases
for tumor modeling include the Mouse Tumor Biology
Database at http://tumor.informatics.jax.org (Naf et al.,
2002), databases accessible through the National Center of
Biotechnology http://www.ncbi.nlm.nih.gov including human and mouse genomes (Wheeler et al., 2003) and The
Whole Mouse Catalog http://www.rodentia.com/wmc/.
Technical Trends in Tumor Modeling
Technical advances in tumor modeling have included use
of skin fold and transparent windows (Dellian et al., 1996; Li
et al., 2000; Jain et al., 2002), matrigel (Eccles, 2002), polymers (Righi et al., 2003), liposomes (Kunstfeld et al., 2003),
chambers (Dvorak et al., 1987) and hollow fibers (Sadar et al.,
2002) to contain tumor growth and monitor angiogenesis. Ex
vivo perfusion (Kristjansen, 2002) and intravital microscopy
are providing insights into drug metabolism, angiogenesis
and in situ tumor responses (Jain et al., 2002).
Improved imaging of tumors has revolutionized noninvasive monitoring of distribution, growth, metastasis and
morphometrics of tumor models in mice. Available systems include micro positron electromagnetic imaging (Ray
et al., 2003; Yang et al., 2003), magnetic resonance imaging (Berr et al., 2003; Nelson et al., 2003), in situ visualization of primary and metastatic tumors and occult metastases
(Menon and Teicher, 2002), using improved fluorochromes
(Rosenberg et al., 2003) and quantum dots (Watson et al.,
2003), green fluorescent protein (GFP) (Hoffman, 2002), and
luciferase (Edinger et al., 1999; Burgos et al., 2003). Improved fluorochromes, GFP, and LacZ (Kruger et al., 1999;
Culp et al., 2001) are also retained within tissues and allow microscopic evaluation by fluorescent microscopy and
histochemical or immunohistochemical staining of tumor
tissues. Laser capture microdissection is a proven technology for identification of genetic heterogeneity of tumors that
continues to expand our knowledge of tumor biology (Culp
et al., 2001; Hoon et al., 2002). Specialized microscopy using confocal (Paddock, 1999) and deconvolution (Maierhofer
et al., 2003) microscopes are also positioned to provide optical sectioning for identification of 3-dimensional distribution of tumor elements and drug distribution within tumors
(Manivasager et al., 2002). While many of these improvements are expensive and impractical for incorporation into
preclinical studies, selective use of advanced technologies
in drug discovery, pharmacology and preclinical studies can
provide minimally invasive and detailed information about
host-tumor-therapeutic interactions in vivo at multiple timepoints.
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Biological Trends: Genetically Engineered Mice
Neoplastic transformation and progression requires a series of genetic alterations that disrupt the balance of cellular mechanisms involving cellular growth and deletion. Mice
have played an important role in defining the genetic mechanisms of carcinogenesis. Thus, it is no surprise that genetically engineered mice (GEM) are beginning to take their
rightful place as models that show accelerated tumor development and recapitulate the genetics and behavior of human cancer states and cancer resistance (Mickisch et al.,
1991; Pitot, 2001; Klatt and Serrano, 2003). Selected target
genetic events allow creation of gene-driven gain of function transgenic, loss of function deletion (Reilly and Jacks,
2001; Meuwissen et al., 2001; Resor et al., 2001; Balmain,
2002; Jackson-Grusby, 2002; Herzig and Christofori,
2002; Tuveson and Jacks, 2002; van Dyke and Jacks,
2002), conditional function (Jonkers and Berns, 2002), clones
(Rideout III et al., 2000) and phenotypically-driven N -ethylN -nitrosourea mutants (Justice et al., 1999; Balmain, 2002).
Although genetically engineered mice have been advocated
for preclinical testing (Feitelson and Larkin, 2001; Horig
et al., 2001), problems associated with these models include
discordance in etiology and histogenesis between human and
mouse tumors, multifocal tumors due to multi-tissue deletions or promotor promiscuity, failure to metastasize, variable penetrance of transgenes, long latency (Rosenberg and
Bortner, 1999; Moore and Nagle, 2000), limited availability,
lack of extensive historical pathology databases for founder
strains (FVB, 129 strains, BALB/c), and costs and effort in
creating and maintaining specialized GEM animal colonies.
Regardless, the ability to use GEM to genetically, anatomically, pathophysiologically and histologically mimic tumors
found in humans is becoming a reality. As more logistical
problems are overcome, these genomic-derived models will
likely become more consistently incorporated into preclinical
testing. Compared to transplantation models, GEM will be
particularly useful to create tumor states that were previously
difficult to model including nervous system (Gutmann et al.,
2003), pancreas (Hotz et al., 2000; Bardeesy et al., 2001),
lung (Tuveson and Jacks, 1999; Liu and Johnston, 2002),
breast (Hutchinson and Muller, 2000), ovarian (Rahman
et al., 1998; Rahman and Huhtaniemi, 2001; Orsulic et al.,
2002), prostate (Sharma and Schreiber-Agus, 1999; Navone
et al., 1999), oral (Opitz et al., 2002), liver (Fausto,
1999; Feitelson and Larkin, 2001; Koike, 2002), hematologic malignancies (Bernardi et al., 2002; Herzig and
Christofori, 2002), pediatric tumors (Beltinger and Debatin,
2001; Houghton et al., 2002), gene-environment interactions
(Hursting, 1997), and metastases (McClatchey, 1999; Herzig
and Christofori, 2002), and to test interventional feasibility
for novel therapeutics against bone metastasis (Fausto, 1999),
cell adhesion dysfunction (Herzig and Christofori, 2002),
telomere dysfunction (Goytisolo and Blasco, 2002; Artandi,
2002; Granger et al., 2002), ribosomal RNA modification
(Ruggero et al., 2003), and DNA hypomethylation (Goodman and Watson, 2002; Gaudet et al., 2003). Despite these
ongoing advances in model systems, disease states associated
with tumors such as minimal residual disease (Teicher, 1997;
Wetterwald et al., 2002), concurrent opportunistic infections,
and treatments such as surgical debulking and combination
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therapy will continue to resist modeling in mice for practical
and humane concerns.
Biological Trends: Modified Immunodeficient Mice
Nude (athymic) and C.B-17 SCID (T and B cell deficient
mice) fail to reject engraftment with a variety of human and
mouse tumor cells (Pettaway et al., 1996; Lapidot et al., 1997;
Bankert et al., 2002; Giovanella, 2002; Uckun and Sensel,
2002) by virtue of their T and B cell defects. The presence of
innate immunity, particularly natural killer (NK) cell activity is probably an important factor in limiting tumorigenesis
and metastases in these models. The nude mutation results in
a mouse that is T cell deficient and has B cell maturational
defects, but with intact innate immunity including tumoricidal macrophages and an increase in NK cells. This mutation has been introduced into many mouse strains. Introduction of the beige mutation blocks NK and myeloid-derived
cell activity and additional B cell defects result by crossing
with the X-linked immunodeficiency mouse. The Chédiak–
Higashi syndrome (hypopigmentation, bleeding diathesis and
recurrent bacterial infections) in mice or hybrids with the
beige anomaly limits their usefulness in surgical, including
orthotopic models (Clarke, 2002). The T and B cell deficient SCID mouse has been particularly amenable to further manipulation and modifications involving expanded immunodeficiencies and “humanization.” These mice are useful
for mechanistic studies and for evaluating anti-tumor therapies on human xenografts (Bankert et al., 2001). However,
NK cell activity and the tendency of some SCID mice to
become “leaky” and develop active T and B cells, and early
onset lymphoproliferative diseases can be problematic. Introduction of the nonobese diabetic (NOD) mutation and recombination activating gene (Rag) deficiency are useful modifiers
for the SCID mutation (Clarke, 2002; Eccles, 2002). The
NOD mouse is a complex model of immune defects that includes autoimmune mediated type-1 diabetes and sialitis, and
Rag-1 and Rag-2 null state produces a severe combined immunodeficiency. Combination of these mutations with SCID
defects results in mice that are no longer leaky and NK
cell activity is reduced while retaining the ability to support
xenografts (Bankert et al., 2001).
SCID or NOD-SCID mice made chimeric with implanted
human lymphoid tissues, peripheral blood cells or bone marrow cells are the most commonly used “humanized” mouse
models. These models have been generated to provide surrogate human microenvironments and to test immunotherapies
(Bankert et al., 2001). Anti-tumor responses in humanized
mouse models have not been extensively validated and their
use supplements rather than supplants other mouse models
for antitumor testing.
Biological Trends: Orthotopic Models
Less than ideal growth and behavior of heterotopic implants has lead to development and characterization of surgical and cellular orthotopic implants (Manzotti et al., 1993).
Both normal and neoplastic cells (individual or clusters) and
histologically intact tissues, of fetal and adult origin can be
used in syngeneic and xenogeneic orthotopic mouse systems.
Normal tissues can be implanted and mice injected with tumor cells to produce an improved metastatic model, and using tumor cells with a reporter gene allows enhanced imaging
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capabilities. Implantation of tumor tissue into anatomically
correct tissue for the histogenesis of the tumor (i.e., kidney
tumor in kidney) rather than heterotopic implantation promotes improved tumor growth and metastases (Naito et al.,
1987a, 1987b; Menon and Teicher, 2002). Orthotopic models also allow correlation of experimental responses with the
original tumor in the host (Steel, 1987).
Although orthotopic models have been utilized for many
years, the need for surgical manipulation in many of the models and need for a fresh source of human tissues (normal or
neoplastic) adds to the difficulty and expense of this type of
implantation. Regardless, orthotopic models provide a useful
model for establishing tumors previously difficult to model
(Fu et al., 1992; Furukawa et al., 1993a, 1993b; An et al.,
1999; Myers et al., 2002) and can be used alone or in combination with humanized mice (Klausner, 1999; Kunstfeld et al.,
2003). Orthotopic models allow efficacy testing for tumor
inhibition and metastases (Menon and Teicher, 2002; Zhang
et al., 2002; Boyd et al., 2003) and appear to be better predictors of clinical success than heterotopic models (Kuo et al.,
1993; Manzotti et al., 1993; Killion et al., 1999; Hoffman,
1999; Bloomston et al., 2002).
Other Animal Models for Preclinical Efficacy Studies
Their size, fecundity, ease of handling, relatively economical production and care (excluding genetically altered
mice), strain selection, and short gestation backed by massive
databases of susceptibilities, genetics, immunology, physiology, pathology, and microbiology make mice an ideal candidate for tumor biology and preclinical efficacy studies. Rats
and hamsters are also useful for biological and therapeutic
modulation because of their propensity to develop a variety of spontaneous tumors, their amenability to tumor implantation, availability of cell lines (Schwartz and Gu, 2002;
Thompson and Sporn, 2002), and recent development of genetically altered rats lacking suppressor genes linked to breast
and ovarian cancer (Zan et al., 2003). Beyond rodents, a limited number of spontaneous neoplasms in companion and domestic animals (Vail and MacEwen, 1997; Knapp and Waters,
1997; Dewhirst et al., 2002) and other species including genetically altered fish (Vanchieri, 2001; Spitsbergen and Kent,
2003) also have some potential value in preclinical efficacy
testing. Dogs, particularly older males provide a very useful model of prostatic disease (Waters and Bostwick, 1997;
Waters et al., 1998; Strandberg, 2000) and dogs larger than
purpose-bred Beagles are often the only relevant model to test
medical devices or device/drug combinations for anti-tumor
applications.
TOWARDS AN IDEAL PRECLINICAL EFFICACY
TESTING PROGRAM
In order to transition into clinical trials, regulatory agencies must be provided with evidence that the new therapeutic has an improved safety and/or efficacy profile compared
to current therapies. Therefore, selection of tumor models
in mice is best approached by using specific criteria that
match biologic (multistage, clonal, progression, histomorphology, and metastasis), genetic (multiple mutations, altered
chromosomes and cell signaling, genetic expression profile
and susceptibility), inductive etiology (chemicals, UV light,
diet, hormones and viral), immunogenicity and therapeutic
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FIGURE 1.—A guide for preclinical efficacy testing of anti-tumor therapeutics. In addition to toxicokinetics (TK) and absorption, distribution, metabolism and
excretion (ADME) studies, development programs should progress through an increasingly complex series of tumors in one or more mouse models, genetically
engineered mice (GEM) and suitable models in other species. Once a probable level of efficacy is established by use of stringent endpoints in multiple models,
an investigational new drug (IND) application may be feasible. Safety studies in tumor-bearing mice should be considered to evaluate toxicity during altered host
homeostasis. If insufficient efficacy is established, additional studies utilizing orthotopic models, GEM and combination therapy models may be necessary to provide
sufficient evidence of probable clinical efficacy. Well-characterized orthotopic and GEM models may be biologically superior to testing in other models and may
provide a shortcut (dotted line) to demonstrating efficacy.

potential (target and predictivity for clinical success) between
mice and humans (Siemann, 1987; Hann and Balmain, 2001;
Balmain, 2002). Although a generic program is not advocated, in vivo preclinical efficacy programs for anti-tumor
therapeutics should follow a guide for testing similar to that
outlined in Figure 1. After selecting the appropriate dose
and scheduling, an efficacy program most economically progresses from simple to more complex tumor model systems.
Use of one or more simple models alone to determine possible clinical efficacy is contrary to the complexity and issues
associated with tumor models in mice and the variation in
accepted therapeutic protocols in clinical oncology. Utilizing
multiple surrogate models (cells and explants, different stains
of mice and/or additional species, different tumor stages),
transplants using variants of the target tumor, and tumor testing in genetically altered animals begins to provide sufficient
efficacy data that can support an IND application. This efficacy data should be accompanied by results from PK and
ADME studies that evaluate kinetics in one or more tumor
model systems. The IND application can also be strengthened by conducting safety studies in tumor-bearing animals
as a model to mimic altered homeostasis in tumor-bearing
humans.
Ideally, the IND should only be filed after completion of
additional preclinical studies that match the genetic heterogeneity of human tumors (multiple animal and tumor models), at least partially match tumor prone genetic profiles in a
tumor-bearing host (genetically altered animals), match tissue tropism (orthotopic models), and match the most accepted

therapeutic protocols (combination therapy models). In some
cases, the most appropriate models will be GEM or orthotopic
models and a limited number of studies in standard mouse
models are justified. Incorporation of multiple levels of efficacy testing along with careful selection of endpoints will
lead to a development program that most closely matches
molecular targets, therapeutic protocols and outcomes encountered in the clinic. Testing through all tiers may not be
applicable or warranted and completion of all steps is not
a guarantee of correlation with clinical efficacy. However, a
thorough preclinical efficacy program provides greater assurance of potential therapeutic efficacy and safety than tumor
modeling restricted to one or two implanted tumors in a single strain of mouse. The expense of comprehensive modeling and additional time spent in preclinical testing is modest
compared to failure in phase II and phase III clinical trials.
SUMMARY
Transitions from in vitro to preclinical and then to clinical testing for tumor modulation remain difficult with a low
rate of clinical entry for most therapeutic classes. Increased
understanding of mechanisms of neoplasia through macromolecular biology, genomics and bioinformatics is helping
to address treatment bottlenecks such as lack of specificity,
low efficacy, toxicity and drug resistance, and helping to
identify critical targets for clinical exploitation. In addition
to cytotoxic, hormonal, adjunct, and medical device therapies, numerous novel strategies for enhanced and targeted
drug deliver, anti-angiogenesis (inhibitors and enhanced
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permeation), immunotherapy (vaccines, monoclonal antibodies, toxin conjugates, prodrug activators, cytokine antagonists), small molecules (inhibitors of growth, matrix and
adhesion), apoptosis (enhancers, inducers, proteasome inhibitors, reverse DNA methylation), anti-sense and gene therapy (tumor suppressor genes) and cell cycle alterations (inhibitors) are being developed for the anti-tumor market. However, our ability to model and accurately predict clinical efficacy is limited. Despite historical significance and ongoing
utility, tumor models in mice used for preclinical therapeutic
intervention often error towards false positive results and curing cancer in mice. The inadequacy of classic transplantation
models for anti-tumor therapy is helping to drive development
and use of new models based on genetic and technical modifications. However, underlying limitations of tumor models
reinforce the need for careful attention to design (applying
correct models to the question), conduct (using multiple models) and interpretation (recognizing limitations and applying
stringent criteria to outcomes) of efficacy studies for tumor
modulation. Animal models can provide quick answers but
application of these results to predicting clinical outcomes is
often undertaken prematurely. New strategies and techniques,
and continued improvements in stringency and consistency
of criteria used for evaluating outcomes will be necessary to
ensure that tumor models in mice remain a useful tool for
development of anticancer agents and devices.
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